Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 10:10 ET | Source: Aclaris Therapeutics, Inc.

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
March 20, 2026 11:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Meeting
March 18, 2026 06:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
March 03, 2026 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 06:58 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
February 04, 2026 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two February Healthcare Conferences

Aclaris Therapeutics to Participate in Two February Healthcare Conferences
January 27, 2026 06:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
January 12, 2026 06:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Aclaris Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with its Novel Bispecific Antibody ATI-052
January 06, 2026 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052